Start 30 days free, no card. Full Pro access for a month, then decide. Start free

Back to analysts list

Analyst

Colleen Babington

Wolfe Research · covers Healthcare

Period: Reporting periods mapped to calendar 2025 Q3 – 2025 Q4 (2 quarters).

Limited coverage. Only 2 questions of coverage. Treat these numbers as directional — sample too small for reliable averages.
Questions
2on tracked calls
Challenge rate
0%none of 2 questionsLimited sample
Companies
1questioned at least once
Reporting periods
2with questions

These figures cover the whole profile: every tracked question, all reporting periods.

How to read these numbers

Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.

Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.

No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.

Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.

Small samples. Profiles with fewer than 10 questions are marked Limited sample.

Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.

Questions asked

Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.

Showing 2 of 2 questions from 1 company

TEMTempus AI, Inc.2 questions · 2 reporting periods · 0 of 2 challenging
TEM company page →

Calendar 2025 Q4

How should we think about the durability of that volume growth into this year and next?

DemandRevenue GrowthTranscript · FY2025 Q4 →
Show response

Jim said Oncology is off to a good start with no massive slowdown; liquid slightly outpaces solid.

Calendar 2025 Q3

We believe that last quarter growth was driven about half by share gains and half by organic expansion.

Competitive DynamicsDemandTranscript · FY2025 Q3 →
Show response

Jim said roughly 50% is share gains, expected to moderate to low-to-mid-20s in Q4.

Challenge rate by company

Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.

CompanyQuestionsChallenge rate
TEM Tempus AI, Inc.2—Rate withheld: fewer than 3 questions
  • TEM
    Tempus AI, Inc. · 2 questions
    —rate withheld: under 3 questions

Activity by reporting period

Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.

Questions by calendar reporting period
Calendar periodQuestionsChallenge rateCompanies
2025 Q310%none of 1 question1
2025 Q410%none of 1 question1
  1. 2025 Q31 question · challenge rate 0% (none of 1 question) · 1 company
  2. 2025 Q41 question · challenge rate 0% (none of 1 question) · 1 company

Topics

Topics tagged on this analyst’s questions.

  • Demand2
  • Revenue Growth1
  • Competitive Dynamics1